TRCT
JUNO

Tower Research Capital (TRC)’s Juno Therapeutics, Inc. JUNO Stock Holding History

Tower Research Capital (TRC)’s Portfolio JUNO Stock Details JUNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-9
Closed – – 4410
2017
Q3 		$0 Sell
9
-16,183
-100% -$552K ﹤0.01% 4399
2017
Q2 		$484K Buy
16,192
+16,190
+809,500% +$400K 0.05% 215
2017
Q1 		$0 Sell
2
-7,445
-100% -$160K ﹤0.01% 4461
2016
Q4 		$140K Buy
7,447
+7,446
+744,600% +$182K 0.02% 806
2016
Q3 		$0 Sell
1
-69
-99% -$2.15K ﹤0.01% 5049
2016
Q2 		$3K Sell
70
-13
-16% -$540 ﹤0.01% 3808
2016
Q1 		$3K Buy
83
+80
+2,667% +$2.79K ﹤0.01% 3241
2015
Q4 		$0 Buy
+3
New +$149 ﹤0.01% 5466
2015
Q3 		– Sell
-10
Closed -$1K – 5258
2015
Q2 		$1K Sell
10
-317
-97% -$16.8K ﹤0.01% 4179
2015
Q1 		$20K Buy
+327
New +$15.9K ﹤0.01% 2266

Other funds holding JUNO

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Tower Research Capital (TRC)'s JUNO Position: Q4 2017 in Review

Tower Research Capital (TRC) sold out of Juno Therapeutics, Inc. (JUNO) in Q4 2017, closing a stake of 9 shares.

Tower Research Capital (TRC) first reported a position in JUNO in Q1 2015 and held it in 10 quarters. The position peaked at $484K in Q2 2017. 237 funds tracked by Wall St. Rank hold JUNO as of Q4 2017.

  • Tower Research Capital (TRC) reported no remaining Juno Therapeutics, Inc. position as of Q4 2017 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 9 Juno Therapeutics, Inc. shares in Q4 2017.
  • Tower Research Capital (TRC) first reported a position in Juno Therapeutics, Inc. in Q1 2015 and held it in 10 quarters.
  • Tower Research Capital (TRC)'s Juno Therapeutics, Inc. position peaked at $484K in Q2 2017.
  • 237 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q4 2017.

Based on Tower Research Capital (TRC)'s 13F filing for Q4 2017, filed 9 Feb 2018.